DX&Vx, Advancing License-In of Patent Technology for Two Microbial Strains

DXVX plans to secure patented technology for two microbial strains and promote commercialization within the first half of this year.

On the 1st, DXVX announced that it will license patented technology for the microbial strains ‘Bacillus coagulans’ and ‘Lactobacillus plantarum,’ registered by the Kori Group in China.

Bacillus coagulans is highly effective in enhancing immune function and inhibiting bacterial growth, while Lactobacillus plantarum regulates intestinal microbiota by promoting beneficial bacteria and suppressing harmful bacteria, as well as providing antioxidant effects. Led by the Kori Group Microbiome Research Institute, the strains were successfully isolated from dairy products and white kimchi, respectively. After more than five years of research, animal model experiments confirmed that these strains activate the immune system and exhibit excellent antioxidant functionality.

Through this licensing, DXVX will acquire the rights to use the patented strains and secure commercialization rights. To target the approximately 50 trillion KRW Chinese health food market, the company plans to register individually recognized health functional foods in China and Korea, conduct additional clinical trials and development, and ultimately expand its business into therapeutic applications using these strains. Additionally, through Korea Bio Pharm and its Chinese subsidiary, DXVX will establish a mass production system for raw materials and products locally in China to supply the Korean, Chinese, and global markets.

A DXVX representative stated, “We plan to further develop strains targeting the global market and expand our product lineup to include biohealthcare products and therapeutics. We will also promote commercialization of various intellectual properties held by the Kori Group, including formulation technologies, through DXVX.”

Meanwhile, DXVX recently acquired approximately 63% of the shares of Evixgen, which holds pipelines related to ophthalmic diseases, and has been steadily recruiting experts in new drug development, focusing on securing pipelines and commercialization. In addition to the two patented strains in China, the company plans to secure various new pipelines.